Taking Lumps From Health Care Reform
This article was originally published in RPM Report
Executive Summary
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
You may also be interested in...
Double Time on Double Dipping: CMS Proposed Rule Puts Pressure On Medicaid Managed Care
New rules on Medicaid managed care plans step up the reporting requirements for tracking drug utilization to assure timely and accurate rebate invoicing. They also include a potentially important clarification on who is responsible for preventing “double-dipping” on 340B products.
The Abbott Split Up: Who Wins?
After implementing a major workforce reduction in January, Abbott Laboratories re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company.
The Public Policy Implications of the Abbott Split
Abbott’s decision to spin-off proprietary pharmaceuticals as a stand-alone company is all about Wall Street: investors cheered the move for “unlocking value” by removing the giant shadow cast by Humira over the diversified base business. But it is also an important touchstone for all the key public policy themes playing out in the biopharma space after health care reform.